Recommendations for the prevention and treatment of influenza using antiviral drugs based on cost–effectiveness

References

• Cox NJ, Subbarao K. Influenza. Lancet354, 1277–1282 (1999).
   PubMed Web of Science ®Google Scholar
• Thompson WW, Shay DK, Weintraub E et al. Influenza-associated hospitalizations in the United States. JAMA292, 1333–1340 (2004).
   PubMed Web of Science ®Google Scholar
• Plans-Rubió P. Prevention and control of influenza in persons with chronic obstructive pulmonary disease. Int. J. Chronic Obs. Pulmonary Dis.2, 41–53 (2007).
   PubMedGoogle Scholar
• Fiore AE, Shay DK, Broder K et al.; CDC Advisory Committee on Immunization Practices. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb. Mortal. Wkly Rep.57(RR07), 1–60 (2008).
   PubMedGoogle Scholar
• NHS. National Institute of Clinical Excellence in the use of zanamivir, oseltamivir and amantadine for the treatment of influenza. Technol. Appraisal58, 1–30 (2003).
   Google Scholar
• Wutzler P, Kossow KD, Lode H, Ruf BR, Scholz H, Vogel GE; Expert Group, German Association for the Control of Virus Diseases and Paul-Ehrlich Society of Germany. Antiviral treatment and prophylaxis of influenza in primary care: German recommendations. J. Clin. Virol.31, 84–91 (2004).
   PubMedGoogle Scholar
• Uhnoo I, Linde A, Pauksens K, Lindberg A, Eriksson M, Norrby R; Swedish Consensus Group. Treatment and prevention of influenza: Swedish recommendations. Scand. J. Infect. Dis.35, 3–11 (2003).
   PubMed Web of Science ®Google Scholar
• Cooper NJ, Sutton AJ, Abrams KR, Wailoo A, Turner D, Nicholson KG. Effectiveness of neuraminidase inhibitors in treatment and prevention of influenza A and B: systematic review and meta-analyses of randomised controlled trials. Br. Med. J.326, 1235 (2003).
   PubMed Web of Science ®Google Scholar
• Wintermeyer SM, Nahata MC. Rimantadine: a clinical perspective. Ann. Pharmacother.29, 299–310 (1995).
   PubMed Web of Science ®Google Scholar
• Antiviral drugs in influenza: an adjunct to vaccination in some situations. Prescrire Int.15, 21–30 (2006).
   PubMedGoogle Scholar
• Saito R, Li D, Suzuki H. Amantadine-resistant influenza A (H3N2) virus in Japan, 2005–2006. N. Engl. J. Med.356, 312–313 (2007).
   Google Scholar
• Hayden FG, Hay AJ. Emergence and transmission of influenza A viruses resistant to amantadine and rimantadine. Curr. Top. Microbiol. Immunol.176, 119–130 (1992).
   PubMed Web of Science ®Google Scholar
• Hayden FG, Gubareva LV, Monto AS et al.; Zanamivir Family Study Group. Inhaled zanamivir for the prevention of influenza in families. N. Engl. J. Med.343, 1282–1289 (2000).
   PubMed Web of Science ®Google Scholar
• Hayden FG, Belshe R, Villanueva C et al. Management of influenza in households: a prospective, randomized comparison of oseltamivir treatment with or without postexposure prophylaxis. J. Infect. Dis.189, 440–449 (2004).
   PubMed Web of Science ®Google Scholar
• Gross PA, Russo C, Dran S et al. Time to earliest peak serum antibody response to influenza vaccine in the elderly. Clin. Diag. Lab. Immunol.4, 491–492 (1997).
   PubMedGoogle Scholar
• Gomolin IH, Leib HB, Arden NH et al. Control of influenza outbreaks in the nursing home: guidelines for diagnosis and management. J. Am. Geriatr. Soc.43, 71–74 (1995).
   PubMed Web of Science ®Google Scholar
• Garner JS; the Hospital Infection Control Practices Advisory Committee. Guideline for isolation precautions in hospitals. Infect. Control Hosp. Epidemiol.17, 53–80 (1996).
   PubMed Web of Science ®Google Scholar
• Patriarca PA, Arden NH, Koplan JP et al. Prevention and control of type A influenza infections in nursing homes. Benefits and costs of four approaches using vaccination and amantadine. Ann. Intern. Med.107, 732–740 (1987).
   PubMed Web of Science ®Google Scholar
• Guay DR. Amantadine and rimantadine prophylaxis of influenza A in nursing homes. A tolerability perspective. Drugs Aging5, 8–19 (1994).
   Google Scholar
• Bowles SK, Lee W, Simor AE et al. Use of oseltamivir during influenza outbreaks in Ontario nursing homes, 1999–2000. J. Am. Geriatr. Soc.50, 608–616 (2002).
   PubMed Web of Science ®Google Scholar
• Schilling M, Povinelli L, Krause P et al. Efficacy of zanamivir for chemoprophylaxis of nursing home influenza outbreaks. Vaccine16, 1771–1774 (1998).
   PubMedGoogle Scholar
• Lee C, Loeb M, Phillips A et al. Zanamivir use during transmission of amantadine-resistant influenza A in a nursing home. Infect. Control Hosp. Epidemiol.21, 700–704 (2000).
   PubMed Web of Science ®Google Scholar
• Parker R, Loewen N, Skowronski D. Experience with oseltamivir in the control of a nursing home influenza B outbreak. Can. Commun. Dis. Rep.27, 37–40 (2001).
   PubMedGoogle Scholar
• Mauskopf JA, Cates SC, Griffin AD, Neighbors DM, Lamb SC, Rutherford C. Cost–effectiveness of zanamivir for the treatment of influenza in a high risk population in Australia. Pharmacoeconomics17, 611–620 (2000).
   PubMed Web of Science ®Google Scholar
• Armstrong E, Khan Z, Perry A, Hons M, Perri L. The cost–effectiveness of zanamivir and oseltamivir for influenza treatment. Formulary35, 979–989 (2000).
   Google Scholar
• Griffin AD, Perry AS, Fleming DM. Cost–effectiveness analysis of inhaled zanamivir in the treatment of influenza A and B in high-risk patients. Pharmacoeconomics19, 293–301 (2001).
   PubMed Web of Science ®Google Scholar
• Husereau D, Brady B, McGeer A. Oseltamivir for the treatment of suspected influenza: a clinical and economic assessment. Canadian Coordinating Office for Health Technology Assessment, ON, Canada (2001).
   Google Scholar
• Brady B, Mc Auley L, Shukla V. Economic evaluation of zanamivir for the treament of influenza. Canadian Coordinating Office for Health Technology Assessment, ON, Canada (2001).
   Google Scholar
• Muennig PA, Khan K. Cost–effectiveness of vaccination versus treatment of influenza in healthy adolescents and adults. Clin. Infect. Dis.331879–1885 (2001).
   PubMed Web of Science ®Google Scholar
• Smith KJ, Roberts MS. Cost–effectiveness of newer treatment strategies for influenza. Am. J. Med.113, 300–307 (2002).
   PubMed Web of Science ®Google Scholar
• Lee PY, Matchar DB, Clements DA, Huber J, Hamilton JD, Peterson ED. Economic analysis of influenza vaccination and antiviral treatment for healthy working adults. Ann. Intern. Med.137, 225–231 (2002).
   PubMed Web of Science ®Google Scholar
• Scuffham P, West P. Economic evaluation of strategies for the control and management of influenza in Europe. Vaccine20, 2562–2578 (2002).
   PubMed Web of Science ®Google Scholar
• Rothberg MB, Rose DN. Vaccination versus treatment of influenza in working adults: a cost–effectiveness analysis. Am. J. Med.118, 70–79 (2005).
   Google Scholar
• Bruls A, Clark W, Stewart T et al. Zanamivir for the treatment of influenza in adults: a systematic review and economic evaluation. Health Technol. Assess.6, 1–87 (2002).
   Google Scholar
• Rothberg MB, Bellantonio S, Rose DN. Management of influenza in adults older than 65 years of age: cost–effectiveness of rapid testing and antiviral therapy. Ann. Intern. Med.139, 321–329 (2003).
   PubMed Web of Science ®Google Scholar
• Rothberg MB, He S, Rose DN. Management of influenza symptoms in healthy adults. J. Gen. Intern. Med.18, 808–815 (2003).
   PubMed Web of Science ®Google Scholar
• Schwarzinger M, Housset B, Carrat F. Bedside rapid flu test and zanamivir prescription in healthy working adults: a cost–benefit analysis. Pharmacoeconomics21, 215–224 (2003).
   Google Scholar
• O’Brien BJ, Goeree R, Blackhouse G, Smieja M, Loeb M. Oseltamivir for treatment of influenza in healthy adults: pooled trial evidence and cost–effectiveness model for Canada. Value Health6, 116–125 (2003).
   PubMed Web of Science ®Google Scholar
• Turner D, Wailoo A, Nicholson K, Cooper N, Sutton A, Abrams K. Systematic review and economic decision modelling for the prevention and treatment of influenza A and B. Health Tech. Assesss.7, 1–170 (2003).
   PubMedGoogle Scholar
• Sander B, Gyldmark M, Hayden FG, Morris J, Mueller E, Bergemann R. Influenza treatment with neuraminidase inhibitors: cost–effectiveness and cost–utility in healthy adults in the United Kingdom. Eur. J. Health Econ.6, 2442–2452 (2005).
   Google Scholar
• Sander B, Hayden FG, Gyldmark M, Garrison LP Jr. Post-exposure influenza prophylaxis with oseltamivir: cost–effectiveness and cost utility in families in the UK. Pharmacoeconomics24, 373–386 (2006).
   PubMed Web of Science ®Google Scholar
• Risebrough NA, Bowles SK, Simor AE, McGeer A, Oh PI. Economic evaluation of oseltamivir phosphate for postexposure prophylaxis of influenza in long-term care facilities. J. Am. Ger. Soc.53444–451 (2005).
   PubMed Web of Science ®Google Scholar
• Roche Tamiflu (oseltamivir) influenza prophylaxis: Achieving Clinical Excellence in Influenza Prophylaxis. Roche submission to the National Institute for Health and Clinical Excellence (2007).
   Google Scholar
• Demicheli V, Jefferson T, Rivetti D, Deeks J. Prevention and early treatment of influenza in healthy adults. Vaccine18, 957–1030 (2000).
   PubMed Web of Science ®Google Scholar
• Tappenden P, Jackson R, Cooper K et al. Oseltamivir, amantadine and zanamivir for the prophylaxis of influenza (including a review of existing guidance no. 67). Health Tech. Assess. (2008) (In Press).
   Google Scholar
• Appleby J, Vevlin N, Parkin D. NICE’s cost–effectiveness threshold. Br. Med. J.335, 358–359 (2007).
   PubMed Web of Science ®Google Scholar
• Cost–Effectiveness in Health and Medicine. Gold MR, Siegel JE, Russell LB, Weinstein MC (Eds). Oxford University Press, NY, USA (1996).
   Google Scholar
• Drummond MF, Sculper MJ, Torrance GW, O’Brien BJ. Methods For The Economic Evaluation Of Health Care Programmes. Oxford University Press, Oxford, UK (1997).
   Google Scholar
• Webster RG, Bean WJ, Gorman OT, Chambers TM, Kawaoka Y. Evolution and ecology of influenza viruses. Microbiol. Rev.56, 152–179 (1992).
   PubMedGoogle Scholar
• Palese P, Young JF. Variation of influenza A, B and C viruses. Science92, 1468–1474 (1982).
   Google Scholar
• WHO Guidelines on the use of vaccines and antivirals during influenza pandemics. WHO, Geneva, Switzerland (2004).
   Google Scholar
• Siddiqui MR, Edmunds WJ. Cost–effectiveness of antiviral stockpiling and near-patient testing for potential influenza pandemic. Emerg. Infect. Dis.14(2), 267–274 (2008).
   PubMed Web of Science ®Google Scholar